Biomarkers for improving the (cost-)effectiveness and safety of pemetrexed

Biomarkers for improving the (cost-)effectiveness and safety of pemetrexed - biomarkers and pemetrexed

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39476

Enrollment

200

Registered

2012-08-30

Start date

2012-10-24

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer non small cell lung carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: patients with non-small cell, non-squamous lungcarcinoma or malignant pleural mesothelioma who have an indication for treatment with pemetrexed containing chemotherapy, both in first line treatment as in following treatment lines and as maintenance therapy.

Exclusion criteria

Exclusion criteria: non able to read dutch clinical condition not fit to receive pemetrexed chemotherapy

Design outcomes

Primary

Measure	Time frame
This is an observational study. The primairy outcome is the question whether there is a relation between pharmacogenetics and pharmacokinetics and repons to treatment with pemetrexed	—

Secondary

Measure	Time frame
relation between pharmacogenetics and pharmacokinetics and quality of life	—

Countries

Netherlands

Outcome results